The choice of the somatic cell for reprogramming, the reprogramming technology chosen, and the differentiation techniques utilised, all work synergistically towards the production of mature iPSCs -
derived chondrocytes which are comparable to patient -
derived chondrocytes, in line with Good Manufacturing Practice guidelines for an «off - the - shelf» stem cell product.
In an attempt to bring patient - specific induced pluripotent stem cell (iPSCs) technology closer to the clinic, researchers have created iPSCs from patient -
derived chondrocytes, using an non-integrative reprogramming method, and used these to then create large numbers of cartilage producing cells.
Not exact matches
Autologous bone marrow -
derived mesenchymal stem cells versus autologous
chondrocyte implantation: an observational cohort study.
In addition to iPS cells
derived from progeria - patients, the researchers successfully applied their method to adult mesenchymal stem cells, which can differentiate into a variety of cell types, including adipocytes, osteoblasts,
chondrocytes, cardiomyocytes, and, as described lately, beta - pancreatic islets cells.
Both control iPSCs
derived from BJ fibroblasts (f - iPSCs) and
chondrocyte derived - iPSCs (C - iPSCs) were fully pluripotent and genomically stable (See figure), and were first differentiated in a monolayer exposing the iPSCs in a defined, three stage manner to activin A, WNT3A, FGF2, BMP4, follistatin, GDF5, and neurotrophin 4.